Remimazolam use in obstetric patients: a single-center retrospective study (2021–2024)
An erratum to this article was published (Int J Obstet Anesth, Aug 2026 ↗)
Authors' conclusion
While preliminary findings are encouraging, the current evidence is limited by the small cohorts evaluated in studies.
Study context
- Population
- Obstetric patients receiving remimazolam (labour analgesia, caesarean delivery, termination of pregnancy, procedural sedation during obstetric care)case reports, case series, RCTs
- Outcome
- Remimazolam use in obstetric anaesthesia
Methodological detailsno restrictions on study design or manuscript type, grey literature and non-peer-reviewed sources excluded, PubMed and Ovid searched, inception to April 1, 2025, English-language manuscripts
- No restrictions on study design or manuscript type
- Grey literature and non-peer-reviewed sources excluded
- PubMed and Ovid searched, inception to April 1, 2025, English-language manuscripts
Main finding
As reported in the abstract
- Remimazolam may be safely used in high-risk obstetric populations including those with maternal cardiac disease, providing effective sedation, stable haemodynamics, high patient satisfaction and favourable maternal-fetal outcomes
- Availability of flumazenil as a reversal agent adds a safety margin
- Literature primarily case reports, case series and RCTs (counts not printed)
Original publication
Remimazolam use in obstetric patients: a single-center retrospective study (2021–2024). Int J Obstet Anesth. Published 8 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →